Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional

Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839

ClinicalTrials.gov ID: NCT02306811

Public ClinicalTrials.gov record NCT02306811. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Long-Term Follow-up Study Assessing the Safety and Efficacy of Vatelizumab in Multiple Sclerosis (MS) Patients Who Completed Treatment in Study DRI13839

Study identification

NCT ID
NCT02306811
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Genzyme, a Sanofi Company
Industry
Enrollment
62 participants

Conditions and interventions

Interventions

  • Vatelizumab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2015
Primary completion
Mar 31, 2016
Completion
Jun 30, 2016
Last update posted
Dec 20, 2016

2015 – 2016

United States locations

U.S. sites
6
U.S. states
5
U.S. cities
6
Facility City State ZIP Site status
Investigational Site Number 840004 Cullman Alabama 35058
Investigational Site Number 840005 Fort Collins Colorado 80528
Investigational Site Number 840007 Ormond Beach Florida 32174
Investigational Site Number 840001 Latham New York 12210
Investigational Site Number 840003 Round Rock Texas 78681
Investigational Site Number 840016 San Antonio Texas 78258

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02306811, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 20, 2016 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02306811 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →